【ashlesha and purva phalguni compatibility】Gene Therapy Market to Surpass $6.21 Billion Globally, by 2027 at 13.4% CAGR: Allied Market Research
Increase in awareness in regards with the benefits of using gene therapy as compared to conventional therapy for the treatment of various diseases and government support to promote gene therapy related research are the major driving factors.
Portland,ashlesha and purva phalguni compatibility OR, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “
Gene Therapy Market
by Vector Type (Viral Vector and Non-viral Vector), Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), and Application (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases): Global Opportunity Analysis and Industry Forecast, 2019–2026
". According to the report, the global gene therapy industry was pegged at $393.35 million in 2018, and is projected to reach $6.21 billion by 2026, registering a CAGR of 34.8% from 2019 to 2026.
Gene therapies are promising therapies applicable to a broad range of diseases; their aim is to radically treat the causes of the diseases instead of only relieving the symptoms. They may be effective on a wide range of previously untreated diseases, such as hematological, ocular, neurodegenerative diseases, and several cancers. For example, adeno associated AAV2 vectors carrying the therapeutic gene (RPE65) intra-retinal injection resulted in improved vision for people with Leber’s Congenital Amaurosis.
Request Sample Report at:
https://www.alliedmarketresearch.com/request-sample/2841
Covid-19 scenario:
The economic crisis would not affect the industry much as the gene therapy operations have not been stopped due to coronavirus pandemic
The demand of gene therapy has not affected by lockdown as it comes under the category of essential goods.
High investment in R&D activities, increase in prevalence of cancer, and growth in awareness regarding gene therapy have boosted the growth of the global gene therapy market. However, high costs associated with gene therapies and unwanted immune responses hamper the market growth. On the contrary, untapped potential for the emerging market is expected to create lucrative opportunities in the near future.
The viral vector segment held the largest share in 2018, contributing to more than half of the global gene therapy market, owing to easier modifications of many viruses such as Lentivirus, Adeno-Associated Virus (AAV), RetroVirus & Gamma RetroVirus to deliver gene therapy drugs. However, the non-viral vector segment is expected to register the fastest CAGR of 38.8% during the forecast period. This is attributed to the technological advancements in physicochemical approaches such as physical methods and chemical methods of non-viral vectors.
Story continues
Get detailed
COVID-19 impact analysis
on the Gene Therapy Market
Request Now!
The tumor suppressor segment to portray the fastest CAGR of 52.9% during the forecast period, owing to rise in number of methodology and clinical trials of tumor suppressor for the gene therapy treatment. However, the antigen segment held the largest share in 2018, contributing to more than one-fifth of the global gene therapy market, due to the presence of a wide range of genetic mutations and dysregulated gene expression of tumor cells.
North America held the largest share in 2018, accounting for nearly half of the market, owing to high prevalence rate of cancer, presence of high disposable income, and increase in funding for R&D activities associated with gene therapy. However, the market across the Asia-Pacific region is projected to register the fastest CAGR of 45.4% during the forecast period, owing to rise in number of people prone to various chronic diseases and approval & launch of gene therapy products.
For Purchase Enquiry at:
https://www.alliedmarketresearch.com/purchase-enquiry/2841
The key players operating in the global gene therapy market include Adaptimmune Therapeutics Plc., Anchiano Therapeutics Ltd., Achieve Life Sciences, Inc., Adverum Biotechnologies, Inc., Abeona Therapeutics Inc., Applied Genetic Technologies Corporation, Arbutus Biopharma Corporation, Audentes Therapeutics, Inc., AveXis, Inc., Bluebird Bio, Inc., Celgene Corporation, CRISPR Therapeutics AG, Editas Medicine, Inc., Editas Medicine, Inc., GlaxoSmithKline Plc., Intellia Therapeutics, Inc., Merck & Co., Inc., Novartis AG, REGENXBIO Inc., Spark Therapeutics, Inc., Sangamo Therapeutics, Inc., Uniqure N. V., Voyager Therapeutics, Inc. Other prominent players in the value chain (companies not profiled in the report) includes Amgen, Epeius Biotechnologies, Sanofi, Juno Therapeutics, and Advantagene.
Similar Reports:
Flow Cytometry Market: Global Opportunity Analysis and Industry Forecast, 2019–2027
Point of Care Diagnostics Market: Global Opportunity Analysis and Industry Forecast, 2019–2027
Contraceptives Market: Global Opportunity Analysis and Industry Forecast, 2019–2027
In Vitro Toxicity Testing Market: Global Opportunity Analysis and Industry Forecast, 2019–2027
About Allied Market Research
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
AMR introduces its online premium subscription-based library
Avenue
, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
Web:
www.alliedmarketresearch.com
Allied Market Research Blog:
https://blog.alliedmarketresearch.com
Follow Us on
|
|
|
|
View comments
本文地址：http://triconsonantalism.cyprusinfo.net/news/343e799649.html
版权声明
本文仅代表作者观点，不代表本站立场。
本文系作者授权发表，未经许可，不得转载。